Reading the annual reports…
First time this company is opened: we are analysing its official reports. This can take up to a minute; after that the page loads instantly.
First time this company is opened: we are analysing its official reports. This can take up to a minute; after that the page loads instantly.
CNC · NYSE · United States · Hospital & Medical Service Plans
In shortCENTENE CORP is loss-making.
Financial health
Solid
Built from five areas over the last five annual reports. Tap an area to see the figures behind it. Bank or insurer: tests that do not apply to them are left out.
| Operating marginShare of each sale left after running the business, before interest and tax. | -3.9% | 4/100 |
|---|---|---|
| Net marginShare of each sale left as profit after every cost, interest and tax. | -3.4% | 6/100 |
| Return on equityProfit earned on the money shareholders put in. Above 15% is strong. | -28.8% | 0/100 |
Weight in the score: 25%
| Free cash flow marginCash left from each sale after investments. The money that can pay dividends or reduce debt. | 2.2% | n/a |
|---|---|---|
| Free cash flow / net incomeHow much accounting profit turns into real cash. Near 1 or above is healthy. | – | n/a |
| Years with positive free cash flow (last 5) | 4 of 5 | n/a |
Weight in the score: 20%
| Profitable years (last 5) | 4 of 5 | 80/100 |
|---|---|---|
| Years of revenue decline (last 5) | 0 of 5 | 100/100 |
| Revenue growth volatility | 5.7% | 90/100 |
| Operating margin volatility | 2.5% | 87/100 |
Weight in the score: 20%
| Revenue growth, 3-year average | 10.5% | 75/100 |
|---|---|---|
| EPS growth, 3-year average | – | n/a |
Weight in the score: 10%
Fiscal year 2025 · change vs prior year
Annual figures as reported. Hover a bar or point for the exact value.
5 older years available with the 10-year history. Essential plan, from €8.25/month →
The last 5 fiscal years from the company's annual reports.
USD millions; negative values in parentheses.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Revenue | 125,982 | 144,547 | 153,999 | 163,071 | 194,777 |
| Cost of revenue | 4,894 | 7,032 | 3,564 | 2,729 | 2,670 |
| Gross profit | 14,487 | 16,918 | 17,637 | 17,069 | 14,209 |
| Selling, general & admin | 9,601 | 11,589 | 12,563 | 12,400 | 12,904 |
| Operating income | 1,784 | 1,318 | 2,930 | 3,175 | (7,623) |
| Interest expense | 665 | 665 | 725 | 702 | 678 |
| Pre-tax income | 1,813 | 1,962 | 3,598 | 4,257 | (6,728) |
| Income tax | 477 | 760 | 899 | 963 | (51) |
| Net income | 1,347 | 1,202 | 2,702 | 3,305 | (6,674) |
| Diluted EPS | $2.28 | $2.07 | $4.95 | $6.31 | −$13.53 |
| Diluted shares (millions) | 591 | 582 | 546 | 524 | 493 |
5 older years available with the 10-year history. Essential plan, from €8.25/month →
Not computed: the model does not apply to banks and insurers.
4/9
Nine yes-or-no tests on profitability, debt, liquidity and efficiency versus the prior year. 7 to 9 is strong, 0 to 3 is weak.
All figures: SEC EDGAR. Ratios and scores are computed by Scorvest (see how it works). Information only, not investment advice. How it works
Latest annual report: Jun 30, 2026 · Data updated Jul 28, 2026